3 news items
Australia Bans Replica Versions Of Popular Weight-Loss Drugs From Novo Nordisk, Eli Lilly On Safety Concerns
LLY
NVO
22 May 24
for safety, quality, or efficacy. Butler noted a rise in reports of adverse events linked to these GLP-1 copies, including a serious incident that resulted
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
AZN
LLY
NVO
12 Apr 24
.
This study, which investigated the incidence of suicidal ideation in overweight patients with type 2 diabetes receiving semaglutide or other non-GLP-1
Pharmacovigilance Risk Assessment Committee Clears GLP-1 Diabetes Medications of Causing Suicidal or Self-Injurious Behavior
LLY
NVO
12 Apr 24
the incidence of suicidal thoughts in patients with overweight and type 2 diabetes mellitus treated with semaglutide or other non-GLP-1 receptor agonist
- Prev
- 1
- Next